Posted by Michael Wonder on 16 Oct 2025
NovelWise Pharmaceutical receives FDA fast track designation for NBM-BMX in metastatic uveal melanoma
14 October 2025 - NovelWise Pharmaceutical today announced that the US FDA has granted fast track designation for NBM-BMX, a selective HDAC8 inhibitor, for the treatment of metastatic uveal melanoma.
The FDA granted the designation based on its review of NovelWise’s robust pre-clinical data in uveal melanoma models together with clinical data from prior Phase I studies of NBM-BMX.
